Cholinesterase inhibition by potato glycoalkaloids slows mivacurium metabolism

Anesthesiology

Volumn 93, Issue 2, 2000, Pages 510-519

  McGehee, Daniel S ^a   Krasowski, Matthew D ^a   Fung, Dennis L ^b   Wilson, Barry ^c   Gronert, Gerald A ^b   Moss, Jonathan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Neuromuscular blocking drugs; Rabbit; Reversal agents; Solanidine

Indexed keywords

ALKALOID DERIVATIVE; ATRACURIUM; CHOLINESTERASE INHIBITOR; CISATRACURIUM; EDROPHONIUM; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PYRIDOSTIGMINE; ROCURONIUM; SOLANINE; VECURONIUM;

ANIMAL EXPERIMENT; ARTICLE; DIETARY INTAKE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MALE; NEUROMUSCULAR BLOCKING; NONHUMAN; POTATO; PRIORITY JOURNAL; RABBIT;

EID: 0033858644     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200008000-00031     Document Type: Article

References (37)

1. Unsolved problems in the cholinergic nervous system
2. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U): A short-acting non-depolarizing ester neuromuscular blocking drug
3. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure
4. Natural inhibitors of cholinesterases: Implications for adverse drug reactions
5. Potato glycoalkaloids: Chemistry, analysis, safety, and plant physiology
6. The toxicity and teratogenicity of Solanaceae glycoalkaloids, particularly those of the potato (Solanum tuberosum): A review
7. Dietary pesticides (99.99% all natural)
8. Solanidine is present in sera of healthy individuals and in amounts dependent on their dietary potato consumption
9. Determination of potato glycoalkaloids and their aglycone in blood serum by high-performance liquid chromatography: Application to pharmacokinetic studies in humans
10. A new and rapid colorimetric determination of acetylcholinesterase activity
11. Aspartate-70 to glycine substitution confers resistance to naturally occurring and synthetic anionic-site ligands on in-ovo produced human butyrylcholinesterase
12. Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations
13. Train-of-four nerve stimulation in the management of prolonged neuromuscular blockade following succinylcholine
14. In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine
15. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE
16. Neuromuscular interactions between mivacurium and esmolol in rabbits
17. Evaluation of solanine toxicity
18. Inhibition of human plasma and serum butyrylcholinesterase by α-chaconine and α-solanine
19. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis
20. The acetylcholinesterase-inhibitory activity of steroidal glycoalkaloids and their aglycones
21. Mivacurium when preceded by pancuronium becomes a long-acting muscle relaxant
22. Residual neuromuscular block is a risk factor for postoperative complications
23. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenedine
24. Grapefruit juice drug interactions
25. Differing potencies of muscle relaxants on rat and guinea-pig phrenic nerve diaphragm preparations
26. Pharmacokinetics, pharmacodynamics and dose-response relationships of atracurium administered i.v.
27. Importance of the organ-independent elimination of cisatracurium
28. Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans
29. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans
30. Pharmacokinetics of edrophonium in anephric and renal transplant patients
31. Clinical pharmacokinetics of cholinesterase inhibitors
32. Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases
33. The inhibition of cholinesterases by pancuronium
34. Inhibition of the plasma cholinesterase variants by pancuronium bromide and some of its analogues
35. An overview of the pharmacology of rocuronium bromide in experimental animals
36. Inhibition of human motor endplate cholinesterase by anticholinesterase compounds